Pierre Fabre, founded in 1962, is a French pharmaceutical and dermo-cosmetics company based in southwest France near Castres. The company operates across 43 locations and distributes products to approximately 130 territories, generating €3.2 billion in revenue in 2025, with 71% coming from international markets. Nearly 90% of manufacturing occurs in France, reflecting a commitment to domestic production.
The company's dermo-cosmetics portfolio includes internationally recognised brands such as Eau Thermale Avène, Klorane, Ducray, Dexeryl, A-Derma, René Furterer and Elgydium. Its pharmaceutical division operates across oncology, dermatology, rare diseases, primary care and family health, positioning Pierre Fabre as one of Europe's leading pharmaceutical laboratories.
Ownership is structured around the Pierre Fabre Foundation, a French government-recognised public-interest foundation that holds 86.3% of the company's capital, with employees holding nearly 10% as the second-largest shareholder group. This structure enables long-term independence and reinvestment. Dividends fund 35 healthcare-access programmes deployed across 22 of the world's least developed countries, linking commercial performance to global health initiatives.